DFTX vs. LRCX

Last updated Jun 3, 2026

DFTX (Definium Therapeutics, Inc) and LRCX (Lam Research Corporation) are both stocks. DFTX operates in Biotechnology (Healthcare), while LRCX operates in Semiconductor Equipment & Materials (Technology). Over the past 3 years, DFTX returned 87.73%/yr vs 79.31%/yr for LRCX. At a 0.22 correlation, their price movements are largely independent.

Performance

DFTX vs. LRCX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Definium Therapeutics, Inc (DFTX) and Lam Research Corporation (LRCX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, DFTX achieves a 70.72% return, which is significantly lower than LRCX's 101.03% return.

DFTX

• 1D: -4.99%
• 1M: 5.35%
• YTD: 70.72%
• 6M: 89.55%
• 1Y: 205.61%
• 3Y*: 87.73%
• 5Y*: —
• 10Y*: —

LRCX

• 1D: 2.78%
• 1M: 32.93%
• YTD: 101.03%
• 6M: 115.41%
• 1Y: 313.85%
• 3Y*: 79.31%
• 5Y*: 40.79%
• 10Y*: 47.12%

*Multi-year figures are annualized to reflect compound growth (CAGR)

DFTX vs. LRCX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
DFTX Definium Therapeutics, Inc	70.72%	92.39%	90.16%	66.36%	-76.86%
LRCX Lam Research Corporation	101.03%	139.16%	-6.84%	88.63%	5.24%

Correlation

The correlation between DFTX and LRCX is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.16
Correlation (3Y) Calculated over the trailing 3-year period	0.20
Correlation (All Time) Calculated using the full available price history since Jul 12, 2022	0.22

Fundamentals

Market Cap DFTX : $2.49B LRCX : $434.03B
EPS DFTX : -$2.57 LRCX : $5.29
PB Ratio DFTX : 8.92 LRCX : 41.01
Total Revenue (TTM) DFTX : $0.00 LRCX : $21.68B
Gross Profit (TTM) DFTX : $0.00 LRCX : $10.84B
EBITDA (TTM) DFTX : -$206.36M LRCX : $6.10B

Return for Risk

DFTX vs. LRCX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DFTX

DFTX Risk / Return Rank: 94
DFTX Sharpe Ratio Rank: 95
DFTX Sortino Ratio Rank: 92
DFTX Omega Ratio Rank: 89
DFTX Calmar Ratio Rank: 96
DFTX Martin Ratio Rank: 97

LRCX

LRCX Risk / Return Rank: 98
LRCX Sharpe Ratio Rank: 99
LRCX Sortino Ratio Rank: 98
LRCX Omega Ratio Rank: 97
LRCX Calmar Ratio Rank: 99
LRCX Martin Ratio Rank: 99

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DFTX vs. LRCX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Definium Therapeutics, Inc (DFTX) and Lam Research Corporation (LRCX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DFTX	LRCX	Difference
Sharpe ratio Return per unit of total volatility	3.35	6.34	-2.99
Sortino ratio Return per unit of downside risk	3.61	5.04	-1.43
Omega ratio Gain probability vs. loss probability	1.42	1.67	-0.25
Calmar ratio Return relative to maximum drawdown	8.67	15.81	-7.14
Martin ratio Return relative to average drawdown	25.65	53.72	-28.07
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DFTX vs. LRCX - Sharpe Ratio Comparison

The current DFTX Sharpe Ratio is 3.35, which is lower than the LRCX Sharpe Ratio of 6.34. The chart below compares the historical Sharpe Ratios of DFTX and LRCX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	DFTX	LRCX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.35	6.34	-2.99
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.89	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	1.06	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.30	0.44	-0.13

Drawdowns

DFTX vs. LRCX - Drawdown Comparison

The maximum DFTX drawdown since its inception was -86.01%, roughly equal to the maximum LRCX drawdown of -87.90%. Use the drawdown chart below to compare losses from any high point for DFTX and LRCX.

Drawdown Indicators

	DFTX	LRCX	Difference
Max Drawdown Largest peak-to-trough decline	-86.01%	-87.90%	+1.89%
Max Drawdown (1Y) Largest decline over 1 year	-24.79%	-20.01%	-4.78%
Max Drawdown (3Y) Largest decline over 3 years	-58.38%	-47.10%	-11.28%
Max Drawdown (5Y) Largest decline over 5 years	—	-56.39%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-56.39%	—
Current Drawdown Current decline from peak	-5.50%	0.00%	-5.50%
Average Drawdown Average peak-to-trough decline	-51.64%	-28.19%	-23.45%
Ulcer Index Depth and duration of drawdowns from previous peaks	8.38%	5.87%	+2.51%

Volatility

DFTX vs. LRCX - Volatility Comparison

Definium Therapeutics, Inc (DFTX) and Lam Research Corporation (LRCX) have volatilities of 15.66% and 16.14%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DFTX	LRCX	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.66%	16.14%	-0.48%
Volatility (6M) Calculated over the trailing 6-month period	38.92%	40.20%	-1.28%
Volatility (1Y) Calculated over the trailing 1-year period	61.78%	49.88%	+11.90%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	84.11%	45.94%	+38.17%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	84.11%	44.58%	+39.53%

Dividends

DFTX vs. LRCX - Dividend Comparison

DFTX has not paid dividends to shareholders, while LRCX's dividend yield for the trailing twelve months is around 0.29%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
DFTX Definium Therapeutics, Inc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
LRCX Lam Research Corporation	0.29%	0.57%	1.19%	0.95%	1.53%	0.78%	1.04%	1.54%	2.79%	1.01%	1.28%	1.36%

Financials

Frequently Asked Questions

Can I hold both DFTX and LRCX in my portfolio?

DFTX and LRCX have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, DFTX or LRCX?

LRCX has higher volatility (16.14%) compared to DFTX (15.66%). In terms of maximum drawdown, DFTX dropped -86.01% vs LRCX's -87.90%.

Which has better risk-adjusted returns?

LRCX currently has the higher Sharpe Ratio (6.34 vs 3.35), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.